Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
5 pending office actions • 2 art units • 3 examiners • 0 of 5 (0%) have an AI response strategy ready
Kiverdi Inc. manages 5 pending office actions in the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 3 distinct examiners across 2 distinct art units. Busiest examiner ARIANI, KADE is responsible for 3 pending office actions. This indicates a concentration of the company's 5 pending office actions under a single examiner, despite the involvement of 2 distinct art units.
For a practitioner, the fact that ARIANI, KADE handles 3 pending office actions means that this examiner's preferences will significantly influence the company's overall prosecution success. Although there are 3 distinct examiners in total, the majority of the 5 pending office actions are centralized. The presence of 2 distinct art units suggests that the technical scope of the applications is relatively narrow, even if they fall under different classifications.
Managing 5 pending office actions with such a high concentration under ARIANI, KADE allows for a more unified prosecution strategy. The company can leverage its experience with this specific examiner across 3 pending office actions to improve outcomes. Meanwhile, the involvement of 2 distinct art units requires the legal team to remain mindful of the different technical standards that may apply to the remaining cases in the Biotechnology & Pharmaceuticals area.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (20%) |
| Double-patenting + other | 3 (60%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ARIANI, KADE | 3 | 75.0% | +32.0% |
| MORENO, LARK JULIA | 1 | 0.0% | +0.0% |
| BERKE-SCHLESSEL, DAVID W | 1 | 66.8% | +31.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18938630 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | ARIANI, KADE | — |
| 18574148 | REDUCTION OF ENDOTOXINS IN BACTERIAL PROTEIN PREPARATIONS | MORENO, LARK JULIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18938630 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | ARIANI, KADE | — |
| 18823526 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | ARIANI, KADE | — |
| 18823534 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | ARIANI, KADE | — |
| 18560290 | HIGH PRODUCTIVITY BIOPROCESSES FOR THE MASSIVELY SCALABLE AND ULTRA-HIGH THROUGHPUT CONVERSION OF CO2 INTO VALUABLE PRODUCTS | BERKE-SCHLESSEL, DAVID W | — |
| Art Unit | Apps |
|---|---|
| 1651 | 4 |
| 1793 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18938630 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | ARIANI, KADE | 1651 | §101§102§112Other | Non-Final OA | — | Pending | Nov 06, 2024 |
| 18823526 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | ARIANI, KADE | 1651 | §112DP | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18823534 | MICROORGANISMS AND ARTIFICIAL ECOSYSTEMS FOR THE PRODUCTION OF PROTEIN, FOOD, AND USEFUL CO-PRODUCTS FROM C1 SUBSTRATES | ARIANI, KADE | 1651 | §112DP | Non-Final OA | — | Pending | Sep 03, 2024 |
| 18574148 | REDUCTION OF ENDOTOXINS IN BACTERIAL PROTEIN PREPARATIONS | MORENO, LARK JULIA | 1793 | §102§103 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18560290 | HIGH PRODUCTIVITY BIOPROCESSES FOR THE MASSIVELY SCALABLE AND ULTRA-HIGH THROUGHPUT CONVERSION OF CO2 INTO VALUABLE PRODUCTS | BERKE-SCHLESSEL, DAVID W | 1651 | §102§112DP | Non-Final OA | — | Pending | Nov 10, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKiverdi Inc. has 5 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Kade Ariani has the most, with 3 of Kiverdi Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
